Can I read Thyroid Dland Disorders Associated with Combination of Antiangiogenic Agents and Immune Checkpoint Inhibitors: A Pharmacovigilance Study on EtoBox?

Thyroid Dland Disorders Associated with Combination of Antiangiogenic Agents and Immune Checkpoint Inhibitors: A Pharmacovigilance Study by Lujie Zhuge is a scholarly article available to read on EtoBox.

What is Thyroid Dland Disorders Associated with Combination of Antiangiogenic Agents and Immune Checkpoint Inhibitors: A Pharmacovigilance Study about?

Purpose: Immune checkpoint inhibitors (ICIs), including anti-PD-1/L1 therapy and anti-CTLA-4 therapy, were reported with thyroid gland disorders adverse events. Recently, the FDA announced a warning that the combination of navolumab and cabozantinib can cause adrenal insufficiency. We performed a pharmacovigilance study to analyze the association between thyroid gland disorders and the use of ICI, anti-angiogenic agents or the combination treatment by mining the FDA adverse events reporting system (FAERS) database. Methods: Data were searched and analyzed in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. Thyroid gland disorders, including hypothyroidism, hyperthyroidism, autoimmune thyroiditis, were defined by the Medical Dictionary for Regulatory Activities (MedDRA). We conducted disproportionality analysis using reporting odds ratio (ROR). The result was defined as a signal if the lower limit of the 95% confidence interval for ROR is over 2, the number of cases ≥3. And additive and multiplicative models were applied to analyze drug interactions. Results: In the FAERS database, we identified 2862 cases of thyroid gland disorders, and the cases

Author

Lujie Zhuge

Publisher

ACM

Published

2022

Language

EN